This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The 5 Dumbest Things on Wall Street This Week: Sept. 27

Stocks in this article: BBRY AAPL CLDX SEPR AIG FIATY

3. Celldex Shenanigans

Remember the good old days when sell-side analysts would push profitless stocks to drum up investment banking business? You know, those wild and crazy times during the Internet bubble when Wall Street giants like Jack Grubman and Henry Blodget lined their own pockets by setting astronomical price targets on crappy or supremely speculative stocks?

Well, if you are too young to recollect the quid-pro-quo research of the go-go 1990's, or have shuttered those memories forever, have no fear. A classic case was on display in the biotech sector this week and boy did it strike our nostalgia bone.

On Monday, Leerink Swann analyst Howard Liang raised his price target on Celldex Therapeutics (CLDX) from $29 to $45 per share, which implies the company's market value will ultimately be $3.6 billion if it hits Liang's target. Shares of the cancer drug company popped 10% Monday on Liang's cheerleading to $33, giving it an impressive market-cap of $2.7 billion.

Seriously, that's quite a feat for a company with essentially no sales and that Wall Street expects to lose 97 cents a share this year and $1.02 cents in 2014.

So why does Liang believe Celldex is worth $1 billion more today than it was last Friday?

It's because of CDX-1127, an experimental cancer immunotherapy which hasn't yet reported any clinical data in patients. The first human data from a phase I study are expected in early November, but as TheStreet's biotech ax Adam Feuerstein points out, Liang is setting the bar very low for Celldex to clear.

"As a combination partner for immune checkpoint inhibitors such as anti-PD-1 agents, we believe the efficacy bar for CDX-1127 is not high based on our analysis of early clinical data on other IO agents, and we believe any demonstration of single-agent activity coupled with a clean safety profile could position CDX-1127 as one of the leading candidates for PD-1 combination," wrote Liang.

The eagle-eyed Feuerstein also highlights the fact that Celldex raised $90 million this past February in an offering co-managed by Liang's employer Leerink. And one can only imagine that Leerink will be right there should Celldex need to raise additional funds again.

And Liang too, of course, with a pom pom in each hand.

3 of 5

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs